Key result
Using low molecular weight heparin during pregnancy did not significantly increase the risk of peripartum adverse events such as postpartum hemorrhage (OR 1.17) compared to no LMWH use.
Why the study?
To summarize trials evaluating the relationship between low molecular weight heparin use during pregnancy and maternal and fetal peripartum adverse events.
Does Low Molecular Weight Heparin (LMWH) use during pregnancy increase maternal and fetal complications in pregnant women?
Meta-Analysis
Does Low Molecular Weight Heparin (LMWH) use during pregnancy increase maternal and fetal complications in pregnant women?
The use of low molecular weight heparin during pregnancy appears safe, as it does not increase the risk of maternal and fetal peripartum complications.
Answers are grounded in this paper and cite their sources.
Supports LMWH safety in pregnancy without raising key complications; confirms meta-analytic evidence for indicated use.
Introduction: To summarize the trials investigated on relationship between low molecular weight heparin use during pregnancy and peripartum adverse events. Meta-analysis was performed to evaluate the effect of Low Molecular Weight Heparin (LMWH) on maternal and fetal complications. Methods: Electronic research was performed in Cochrane Library, MEDLINE and EMBASE through October 2020. The primary outcome was the incidence of maternal and fetal complications during peripartum period. RevMan 5.3 was used for data analysis. Results: 11 articles were finally included. Meta-analysis showed there was no significant difference in abortion, premature delivery, stillbirth, preeclampsia and postpartum hemorrhage events between pregnant women who used LMWH and those who not. Conclusion: Using LMWH in pregnant women does not increase pregnancy related maternal and fetal complications.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2021) conducted a meta-analysis in Pregnancy requiring anticoagulant therapy. Low Molecular Weight Heparin vs. No LMWH was evaluated on Postpartum hemorrhage (OR 1.17, 95% CI 0.95-1.43, p=>0.05). Using low molecular weight heparin during pregnancy did not significantly increase the risk of peripartum adverse events such as postpartum hemorrhage (OR 1.17) compared to no LMWH use.
Synapse has enriched 10 related papers. Consider them for comparative context: